IBN - 30091

931045311 | 42 PD. AAM-948 TRT

AGENCY FOR INTERNATIONAL DEVELOPMENT

PROJECT DATA SHEET

1. TRANSACTION CODE: [ ] A = Add, C = Change, D = Delete — Amendment Number: _____ — DOCUMENT CODE: 3

2. COUNTRY/ENTITY: S&T Interregional

3. PROJECT NUMBER: 931-0453.11

4. BUREAU/OFFICE: S&T/H [10]

5. PROJECT TITLE (maximum 40 characters): Malaria Immunity - U. Missouri

6. PROJECT ASSISTANCE COMPLETION DATE (PACD): MM DD YY: 10 30 86

7. ESTIMATED DATE OF OBLIGATION (Under "B." below, enter 1, 2, 3, or 4): A. Initial FY 83 B. Quarter 4 C. Final FY 85

8. COSTS ($000 OR EQUIVALENT $1 =)

A. FUNDING SOURCE	FIRST FY 83 B. FX	C. L/C	D. Total	LIFE OF PROJECT E. FX	F. L/C	G. Total
AID Appropriated Total	560		560	2,000		2,000
(Grant)	(560)	( )	(560)	(2,000)	( )	(2,000)
(Loan)	( )	( )	( )	( )	( )	( )
Other U.S. 1.						
Other U.S. 2.						
Host Country						
Other Donor(s)						
TOTALS	560		560	2,000		2,000

9. SCHEDULE OF AID FUNDING ($000)

A. APPROPRIATION	B. PRIMARY PURPOSE CODE	C. PRIMARY TECH. CODE 1. Grant	C. PRIMARY TECH. CODE 2. Loan	D. OBLIGATIONS TO DATE 1. Grant	D. OBLIGATIONS TO DATE 2. Loan	E. AMOUNT APPROVED THIS ACTION 1. Grant	E. AMOUNT APPROVED THIS ACTION 2. Loan	F. LIFE OF PROJECT 1. Grant	F. LIFE OF PROJECT 2. Loan
(1) ST/H	511	542				2,000		2,000	
(2)									
(3)									
(4)									
TOTALS						2,000		2,000	

10. SECONDARY TECHNICAL CODES (maximum 6 codes of 3 positions each)

11. SECONDARY PURPOSE CODE

12. SPECIAL CONCERNS CODES (maximum 7 codes of 4 positions each)

A. Code							
B. Amount							

13. PROJECT PURPOSE (maximum 480 characters)

The purpose of this is to develop a safe and effective merozoite subunit vaccine for human malaria.

14. SCHEDULED EVALUATIONS: Interim MM 12 YY 83 — MM 10 YY 84 — Final MM 10 YY 85

15. SOURCE/ORIGIN OF GOODS AND SERVICES: [X] 000 [X] 941 [ ] Local [ ] Other (Specify) _____

16. AMENDMENTS/NATURE OF CHANGE PROPOSED (This is page 1 of a _____ page PP Amendment)

17. APPROVED BY — Signature: George Curlin — Title: Director, Office of Health — Date Signed: MM 05 DD 31 YY 83

18. DATE DOCUMENT RECEIVED IN AID/W, OR FOR AID/W DOCUMENTS, DATE OF DISTRIBUTION: MM DD YY

AID 1330-4 (8-79)

PROJECT AUTHORIZATION

Name of Entity: Interregional

Project Title: Malaria Vaccine Development

Project No.: 931-0453.11

Grantee: University of Missouri

1. Pursuant to Section 104 of the Foreign Assistance Act of 1961, as amended, I hereby authorize the research project entitled "Malaria Immunity and Immunization" involving not to exceed $2,000,000 of S&T Bureau grant funds over a three year period from the date of authorization subject to the availability of funds in accordance with the A.I.D. OYB/Allotment process to help in financing the costs of the project.

2. The project will conduct research on the intraerythrocytic protozoan agent, Plasmodium falciparum, to develop a vaccine based upon soluable and sub-unit surface coat antigens released by the parasite during infection.

Clearances:

A. ST/H: G.Curlin Date 6/7/83
B. ST/PO: G. Eaton Date 6/6/83

S&T/HP, F. Herder
Acting Agency Director
for Health and Population

6/6/83
(Date)

May 31, 1983

ACTION MEMORANDUM FOR THE ACTING AGENCY DIRECTOR
FOR HEALTH AND POPULATION

FROM: S&T/HP, George Curlin, M.D.

Action: Your approval is requested for a grant of $2,000,000 from Section 104 of the Foreign Assistance Act of 1961 as amended for project 931-0453.11, Malaria Immunity and Vaccination Research, University of Missouri.

Discussion: The project is designed to follow up successful research conducted at the University of Missouri to isolate and fully characterize the antigens of the human blood cell stage of the malaria parasite and demonstrate this antigen's safety and efficacy in animal models. Additionally, the project will investigate the mechanism by which the new in-vitro assay, called the "parasite inhibition test," is able to predict in-vivo protection in Aotus monkeys.

This research project was reviewed by the Agency's external review panel on February 4, 1983 and unanimously approved for funding. According to FPR 1-4.909, the proposed contractor is unique, being the only research group in the world with a merozoite antigen separated by polyacrylamide gel electrophoresis with an RF value of 0.52 corresponding to the protective protein moiety PF 43Kd. This particular moiety has been shown to be protective in in-vitro assays as well as primates and may well be the basis of a protective human malaria vaccine. The training and research experience of the scientists at the University of Missouri is outstanding, the research facilities, especially the Aotus facilites, are unmatched in the world with a veterinary staff of the most experienced Aotus primate specialists currently available.

Justification to the Congress: Project funding is included in the FY 1983 Congressional Presentation, Annex V, Centrally Funded Programs, Page 57.

Clearances Obtained: This project was approved by the AID external expert panel at the February 4, 1983, meeting.

Recommendations: 1. That you sign the attached authorization.
2. That you sign the attached justification for non-competitive procurement.

Attachments:
1. Project Authorization
2. Project Paper

Clearance:
S&T/PO, G.Eaton Date: 6/6/83

3